Research programme: sclerostin inhibitors - Medtronic/OsteoGenix
Latest Information Update: 16 Jul 2016
At a glance
- Originator Osteogenix
- Class
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA
- 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Bone regeneration presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
- 26 Mar 2007 Preclinical trials in Bone regeneration in USA (unspecified route)